A retrospective study analysing Pre-treatment characteristics and long term outcomes of head and neck cancer patients who received ICI for long term
Latest Information Update: 14 Oct 2020
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 14 Oct 2020 New trial record
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress